A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH: APD811-301

  • Brown, Martin (Primary Chief Investigator)
  • Butala, Radhika (Clinical Trial Unit Staff)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleARENA 301
AcronymADVANCE-outcomes
StatusFinished
Effective start/end date17/10/19 → 30/06/22